Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women

Journal of Acquired Immune Deficiency Syndromes

Volumn 55, Issue 3, 2010, Pages 345-350

  Lamorde, Mohammed ^a,b   Byakika Kibwika, Pauline ^a,b,c   Okaba Kayom, Violet ^a   Flaherty, John P ^d   Boffito, Marta ^e   Namakula, Rhoda ^a   Ryan, Mairin ^b   Nakabiito, Clemensia ^a   Back, David J ^f   Khoo, Saye ^f   Merry, Concepta ^a,b,c,g   Scarsi, Kimberly K ^c  

^a MAKERERE UNIVERSITY   (Uganda)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c Infectious Diseases Network for Treatment and Research in Africa INTERACT   (Uganda)

^d NORTHWESTERN UNIVERSITY   (United States)

^e CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

^g ST JAMES S HOSPITAL   (Ireland)

Author keywords

antiretroviral agents; HIV; pharmacokinetics; pregnancy; Sub Saharan Africa

Indexed keywords

NEVIRAPINE; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG MONITORING; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTRAPARTUM CARE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; PUERPERIUM; SECOND TRIMESTER PREGNANCY; STEADY STATE; THIRD TRIMESTER PREGNANCY; UGANDA; ADOLESCENT; CHEMISTRY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; LONGITUDINAL STUDY; PLASMA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; NEVIRAPINE; PLASMA; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; UGANDA; VIRAL LOAD; YOUNG ADULT;

EID: 78049272719     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181e9871b     Document Type: Article

References (33)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Report on the Global AIDS Epidemic. Geneva, Switzerland: UNAIDS 2008.
2. United Nations Children's Fund (UNICEF). Children and AIDS: Third Stocktaking Report. New York, NY: UNICEF, Joint United Nations
3. Programme on HIV/AIDS, World Health Organization and United Nations Population Fund 2008.
4. World Health Organization (WHO). Antiretroviral Therapy for HIV Infection Adults and Adolescents in Resource Limited Settings: Towards Universal Access. Geneva, Switzerland: WHO 2006.
5. Havlir D, Cheeseman SH, McLaughlin M, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis. 1995;171:537-545.
6. World Health Organization (WHO). Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants: Towards Universal Access: Recommendations for a Public Health Approach. Geneva, Switzerland: World Health Organization 2006.
7. United Nations Children's Fund (UNICEF). Scaling up Priority HIV Services for Women and Children in the Health Sector\-Progress Report 2008. New York, NY: UNICEF, Joint United Nations Programme on HIV/ AIDS and the World Health Organization; 2008.
8. Flys TS, Mwatha A, Guay LA, et al. Detection of K103N in Ugandan women after repeated exposure to single dose nevirapine. AIDS. 2007;21: 2077-2082.
9. Wind-Rotolo M, Durand C, Cranmer L, et al. Identification of nevirapine-resistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1. J Infect Dis. 2009;199: 1301-1309.
10. Erickson DA, Mather G, Trager WF, et al. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos. 1999;27: 1488-1495.
11. Cheeseman SH, Hattox SE, McLaughlin MM, et al. Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrob Agents Chemother. 1993;37:178-182.
12. Hebert MF, Easterling TR, Kirby B, et al. Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. Clin Pharmacol Ther. 2008;84:248-253.
13. Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet. 2004;43:1071-1087.
14. Acosta E, Zorrilla C, Van Dyke R, et al. Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. HIV Clin Trials. 2001;2:460-465.
15. Syme MR Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet. 2004;43:487-514.
16. Stek A, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. AIDS. 2006;20:1931-1939.
17. Unadkat JD, Wara DW, Hughes MD, et al. Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother. 2007;51:783-786.
18. van Heeswijk R, Khaliq Y, Gallicano K, et al. The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum. Clin Pharmacol Ther. 2004;76:588-597.
19. Mirochnick M, Best B, Stek A, et al. Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr. 2008;49:485-491.
20. AIDS Clinical Trials Group. Division of AIDS Table for Grading the Severity of Adult and Pediatirc Adverse Events. December 2004. Available at: www3.niaid.nih.gov/LabsAndResources/resources/ DAIDSClnRsrch/PDF/ DAIDSAEGradingTable.pdf. Accessed January 21, 2010.
21. de Vries-Sluijs TE, Dieleman JP, Arts D, et al. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet. 2003;42:599-605.
22. La Porte C, Back D, Blaschke T, et al. Updated guidelines to perform therapeutic drug monitoring for antiretroviral agents. Rev Antivir Ther. 2006;3:4-14.
23. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Pharmacokinetics in Pregnancy\-Study Design, Data Analysis, and Impact on Dosing and Labelling. (draft guidance). Rockville, MD: Food and Drug Administration, Center for Drug Evaluation and Research; 2004.
24. Capparelli EV, Aweeka F, Hitti J, et al. Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. HIV Med. 2008;9:214-220.
25. von Hentig N, Carlebach A, Gute P, et al. A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy. Br J Clin Pharmacol. 2006;62:552-559.
26. Nellen JF, Damming M, Godfried MH, et al. Steady-state nevirapine plasma concentrations are influenced by pregnancy. HIV Med. 2008;9:234-238.
27. Mahungu T, Smith C, Turner F, et al. Cytochrome P450 2B6 516G-T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV Med. 2009;10:310-317.
28. Ciccacci C, Borgiani P, Ceffa S, et al. Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. Pharmacogenomics. 2010;11:23-31.
29. WyenC, Hendra H, VogelM, etal.Impactof CYP2B6983T.Cpolymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother. 2008;61:914-918.
30. Penzak SR, Kabuye G, Mugyenyi P, et al. Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med. 2007;8:86-91.
31. Ioannides J, Abrams E, Ammann A, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads ,1,000 copies.mL-1. J Infect Dis. 2001;183:539-545.
32. Marazzi MC, Germano P, Liotta G, et al. Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women. HIV Med. 2006;7: 338-344.
33. Black V, Rees H. Incidence of nevirapine-associated hepatitis in an antenatal clinic. S Afr Med J. 2008;98:116-118.